

# NHS Ayrshire & Arran



<b>Meeting:</b>	<b>Ayrshire and Arran NHS Board</b>
<b>Meeting date:</b>	<b>Monday 31 January 2022</b>
<b>Title:</b>	<b>Performance Governance Committee meeting on 20 January 2022 report to NHS Board</b>
<b>Responsible Director:</b>	<b>Derek Lindsay, Director of Finance</b>
<b>Report Author:</b>	<b>Bob Martin, Committee Chair</b>

## 1. Purpose

This is presented to the Board for: Discussion.

This paper relates to: Local policy to ensure good governance practice in reporting from board committees

This aligns to the NHS Scotland quality ambitions of Safe, Effective and Person Centred. Good governance practice supports the effective delivery of services across the organisation.

## 2. Report summary

### 2.1 Situation

This report provides information to Board Members on key issues discussed within the Governance Committee's remit, in order to provide assurance to the Board that those matters have been identified and are being addressed, where required.

### 2.2 Background

The Board Model Standing Orders advises that Board meeting papers will include the minutes of committee meetings which the relevant committee has approved. To ensure that there is no delay in reporting from committees this paper provides a timely update on key issues from committees.

### 2.3 Assessment

Key issues agreed by Committee are noted below. Identification of organisational risks, stakeholder considerations and other impacts were included in papers to the Committee.

- An update was provided on the progress of the National Treatment Centre. An evaluation is underway and workshops have been organised to gauge opinions on the options being considered. It is anticipated that the option appraisal will be

completed by mid-February 2022 with the Economic Case being available from March 2022.

- The Financial Management Report for Month 8, up to the end of November 2021 was discussed. A £3.2 million overspend was noted with the three main factors contribution to this being unachieved cash releasing efficiency savings, medical agency spend and an increase in spend for new medicines.
- A cost pressures paper was considered with regard to pay and supplies and although a £20.3 million funding uplift has been granted there is an identified cost pressure around £30 million related to pay and supplies cost pressures. This results in an imbalance between the funding uplift and cost pressures.
- A paper was presented on Prescribing cost pressures. A cost pressure of £13.7 million relates to various increases identified across acute services, GP prescribing and new Medicines. The paper has been submitted to the Realistic Medicines Effective Prescribing Group for consideration.

## **2.4 Recommendation**

The Board is asked to be aware of and discuss the key issues highlighted and receive assurance that issues are being addressed, where required.